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Abstract
Rationale: Albuterol, a bronchodilator medication, is the first-line
therapy for asthma worldwide. There are significant racial/ethnic
differences in albuterol drug response.
Objectives: To identify genetic variants important for
bronchodilator drug response (BDR) in racially diverse children.
Methods:We performed the first whole-genome sequencing
pharmacogenetics study from 1,441 children with asthma from the
tails of the BDR distribution to identify genetic association with
BDR.
Measurements and Main Results:We identified population-
specific and shared genetic variants associated with BDR, including
genome-wide significant (P, 3.533 1027) and suggestive (P,
7.063 1026) loci near genes previously associated with lung capacity
(DNAH5), immunity (NFKB1 and PLCB1), and b-adrenergic
signaling (ADAMTS3 and COX18). Functional analyses of the
BDR-associated SNP in NFKB1 revealed potential regulatory
function in bronchial smooth muscle cells. The SNP is also an
expression quantitative trait locus for a neighboring gene, SLC39A8.
The lack of other asthma study populations with BDR and whole-
genome sequencing data on minority children makes it impossible
to perform replication of our rare variant associations. Minority
underrepresentation also poses significant challenges to identify
age-matched and population-matched cohorts of sufficient sample
size for replication of our common variant findings.
Conclusions: The lack of minority data, despite a collaboration of
eight universities and13 individual laboratories, highlights theurgent
need for a dedicated national effort to prioritize diversity in research.
Our study expands the understanding of pharmacogenetic analyses
in racially/ethnically diverse populations and advances the
foundation for precision medicine in at-risk and understudied
minority populations.
Keywords: albuterol; asthma; minority; NFKB1; Latinos
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Asthma is a chronic inflammatory disorder
characterized by recurrent respiratory
symptoms and reversible airway
obstruction. Asthma is the most common
chronic childhood disease (1). In the United
States, asthma prevalence is highest among
Puerto Ricans (36.5%), intermediate among
African Americans (13.0%) and European
Americans (12.1%), and lowest among
Mexican Americans (7.5%) (2). Asthma
mortality is fourfold to fivefold higher in
Puerto Ricans and African Americans
compared with white persons and Mexican
Americans (3).
Inhaled b2-agonists (e.g., albuterol)
are the preferred treatment for acute
asthma symptoms. Albuterol produces
bronchodilation by causing rapid smooth
muscle relaxation in the airways. Albuterol
is the most commonly prescribed
asthma medication worldwide (4). Among
low-income and minority populations,
albuterol is often the only medication
used for asthma regardless of asthma
severity (5, 6).
Spirometry is used to quantify
bronchodilator drug response (BDR), which
varies significantly among individuals and
between populations (7). Specifically, the
populations with the highest asthma
prevalence and mortality also have the
lowest BDR: Puerto Rican and African
American children have significantly lower
BDR than white and Mexican American
children (7, 8). This racial/ethnic variation
in BDR may contribute to the observed
disparities in asthma morbidity and
mortality (9, 10).
BDR is a complex trait, influenced by
social, environmental, and genetic factors,
with heritability estimates ranging from 47%
to 92% (11–13). Genome-wide association
studies (GWASs) have identified several
common SNPs associated with BDR in
populations of European descent (14–16).
Only one GWAS of BDR has been
conducted among African Americans (17).
Although that study identified a novel
BDR-associated locus, it did not replicate
associations discovered in populations of
European descent, suggesting that BDR
may be partly determined by population-
specific variants. Our genetic investigation
of BDR among Latinos identified a
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significant contribution of population-
specific rare variants (18).
Whole-genome sequencing (WGS) can
identify rare and/or population-specific
disease-causing genetic variants. WGS
allows the detection of common and rare
variants in coding and noncoding regions in
a truly comprehensive and agnostic
evaluation in the context of complex disease.
We performed WGS on 1,441 minority
children with asthma from the tails of the
BDR distribution (see Figure E1 in the
online supplement). We examined high and
low drug responders from three ethnic
groups: Puerto Ricans, Mexicans, and
African Americans. Subject selection and
the main analyses are summarized in
Figure 1. We identified BDR-associated
common and rare variants that are
population-specific or shared among
populations. This study represents a highly
collaborative effort and is part of the
NHLBI TOPMed (Trans-Omics for
Precision Medicine Whole Genome
Sequencing) program. Our study
represents the first WGS study to
investigate genetic variants of BDR in
racially diverse children with asthma.
Some of the results of this study have been
previously reported in the form of conference
abstracts (19–22).
Methods
Study Cohorts and Sample Details
This study examined a subset of subjects
with asthma from SAGE II (Study of
African Americans, Asthma, Genes and
Environments) (23) and GALA II (Genes-
Environments and Admixture in Latino
Americans) studies (18).
A total of 1,441 individuals from three
ethnic groups (483PuertoRicans, 483Mexicans,
and 475 African Americans) representing
the tails of the BDR distribution were
selected for WGS (Figure 1). Sequencing
quality control metrics are summarized in
Table E1. Subject selection and filtering
processes are described in the online
supplement. Descriptive data of study
participants are summarized in Table 1.
Detailed descriptions of BDR assessment
and analysis are described in the online
supplement.
WGS Data Generation, Processing,
and Quality Control
Details regarding DNA processing, WGS,
variant calling, data quality controls, and
variant annotation are described in the
online supplement.
Data Availability
TOPMed WGS data are available to
download by submitting a data access
request through dbGaP. The dbGaP study
accession numbers for GALA II and SAGE
II are phs000920.v1.p1 and phs000921.v1.
p1, respectively.
BDR Association Testing and
Replication
Single and multivariant testing for BDR
association were performed. Logistic
regression analysis (high vs. low responder
status) was controlled for age, sex, body
mass index category, and the first 10
principal components. We conducted
population-specific analyses and also
performed a transethnic meta-analysis using
METASOFT (24). Multivariant analysis was
also performed on individuals combined
across all three populations, including local
genetic ancestries as additional covariates.
The contribution of individual common
and rare variants to multivariant
association significance was evaluated by
excluding common or rare variants in
reduced and drop-one analyses. Variation
in BDR explained by identified associations
was calculated using McFadden pseudo R2
(25). Detailed descriptions of these analyses
are described in the online supplement.
We were unable to identify another age-
and population-matched asthma cohort of
sufficient size to replicate our drug response
findings. Replication was nevertheless
attempted in smaller cohorts and is described
in detail in the online supplement.
Variant Prioritization and Functional
Validation
To prioritize BDR-associated variants for
further evaluation, an H3K27ac chromatin
immunoprecipitation sequencing (ChIP-seq)
assay was performed to identify variants
overlapping with regulatory regions in
primary bronchial smooth muscle cells
(BSMCs). The Diverse Convergent Evidence
approach (26) was then used to score BDR-
associated variants using multiple levels of
observational, bioinformatic, and laboratory
evidence. Prioritized variants were further
validated by luciferase enhancer assays to
verify enhancer activity and by RNA
sequencing to identify potential expression
quantitative trait locus function. Detailed
descriptions of these procedures are
described in the online supplement.
Results
Descriptive Characteristics of Study
Subjects
Descriptive characteristics for all study
subjects (n = 1,441) are summarized in
Table 1. Covariates and demographic
variables were assessed for significant
At a Glance Commentary
Scientific Knowledge on the
Subject: Asthma is the most common
chronic disease among children.
Albuterol, a bronchodilator medication,
is the first-line therapy for asthma
treatment worldwide. In the United
States, asthma prevalence is the highest
among Puerto Ricans, intermediate
among African Americans and white
persons, and lowest inMexicans. Asthma
mortality is fourfold to fivefold higher in
Puerto Ricans and African Americans
compared with Mexicans. Puerto Ricans
and African Americans, the populations
with the highest asthma prevalence and
mortality, also have the lowest albuterol
bronchodilator drug response.
What This Study Adds to the
Field: We conducted the largest
pharmacogenetic study using whole-
genome sequencing data from 1,441
minority children with asthma who
had extremely high or low albuterol
bronchodilator drug response. We
identified population-specific and
shared pharmacogenetic variants
associated with bronchodilator drug
response. We prioritized variants in
NFKB1 with multiple levels of existing
biologic evidence and demonstrated
their potential regulatory functions
using chromatin immunoprecipitation
sequencing, RNA sequencing, and
luciferase enhancer assays. Our study
reveals the challenges and importance
of increasing diversity in research. Our
findings help inform the direction
of future development of asthma
medications and advance the
foundation of precision medicine
for at-risk, yet understudied,
racially/ethnically diverse populations.
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differences between high and low drug
responders for each racial/ethnic group.
Significant differences were found for age
(Mexicans, P, 0.001), baseline lung
function (pre-FEV1% predicted, P, 0.001),
total IgE (P, 0.001), and atopy. Pre-
FEV1% predicted was defined as the
percentage of observed FEV1 relative to the
expected population average FEV1 based on
the Hankinson lung function prediction
equations (27). Results and descriptions of
genetic ancestry and genetic substructure
are shown in Table 1, supplemental text E1,
and Figures E2 and E3.
BDR Association Testing with
Common Variants
Detailed descriptions of variant summary
statistics are described in supplemental text
E2, Figure E4, and Tables E2 and E3. Study
design is described in Figure E5. All
subsequent analyses in this study were
performed only with biallelic SNPs.
Throughout this study, low drug responders
were assigned as the reference (i.e., control)
group, and high drug responders were
classified as cases. We performed genome-
wide association testing of common variants
with BDR (dichotomized as high/low drug
responders) for each population, adjusting
by age, sex, body mass index category, and
the first 10 principal components. We then
performed a transethnic meta-analysis
across all three populations.
The commonly used GWAS P value
threshold of 53 1028 is derived from
a Bonferroni correction under the
assumption of 1,000,000 independent tests,
based primarily on patterns of linkage
disequilibrium (LD) from individuals of
European descent. This threshold has been
shown to be nongeneralizable for genetic
studies among populations of non-
European descent (28, 29). We therefore
empirically calculated the effective number
of independent tests for each population
and for our transethnic meta-analysis.
The resulting genome-wide significance
thresholds were 1.573 1027 for Puerto
Ricans, 2.423 1027 for Mexicans, 9.593
1028 for African Americans, and 3.533
1027 for the transethnic meta-analysis.
These numbers are highly concordant with
WGS significance thresholds derived from
the 1,000 Genomes sequencing data (28).
Significance thresholds for discovery
analyses in GWASs can often produce
false-negative results. To minimize type II
error, suggestive associations are often
included in replication and functional
validation studies. We identified
suggestive associations based on the
following widely used formula:
1/(effective number of tests) (30).
Although no significant associations
were identified from the population-specific
analyses (see Figure E6), our transethnic
meta-analysis identified 10 unique loci
(represented by 27 SNPs) significantly
(P, 3.533 1027) or suggestively (P,
7.063 1026) associated with BDR status
(Figure 2A and Table 2; see Table E4). After
LD pruning, these 27 SNPs explain 23%,
16%, and 18% of the variation in BDR
status in Puerto Ricans, Mexicans, and
African Americans, respectively (see Table
E5). To demonstrate that the results of our
regression models were robust, a post hoc
analysis was performed on the 27 SNPs by
including Native American and African
local ancestries as covariates. The
association results before and after
adjusting for local ancestry remained
consistent (see Text E3, Table E6). We
annotated all 27 SNPs by performing a
thorough bioinformatic search in
ENCODE, the NHGRI-EBL GWAS
Catalog, and PubMed. Their previously
reported lung-related phenotype
associations and functional annotations
are reported in Tables E7 and E8.
Two SNPs located on chromosome 5
(rs17834628 and rs35661809) were
significantly associated with BDR (P =
1.183 1028 and 3.333 1028). The
direction of effect for these two variants is
concordant across all three populations
(Figure 2B; see Table E9). Figure 2C
displays a LocusZoom plot of rs17834628
with 400-kb flanking regions. Three of
the 27 SNPs were located within genes.
Specifically, two SNPs are located in the
third and fifth introns of NFKB1
(rs28450894 and rs4648006), and a third
SNP, rs16995064, mapped to intron 7 of
PLCB1 (Table 2). Based on 1,000 Genomes
data, the low BDR-associated T allele
of NFKB1 (rs28450894) is found
predominantly among African
populations (minor allele frequency
[MAF], 8.8–28.7%), followed by
WGS Study Population Selection
from tails of BDR distribution
WGS Quality Control
Total Available Subjects
GALA II / SAGE II
Subjects with asthma and BDR
Common variant
Meta-analysis Combined
Logistic regression SKAT-O, 1kb, 500bp increment
Common and rare variant
5,575 Subjects
1,484 Subjects
2,319 PR
1,556 MX
1,700 AA
PR
MX
AA
PR
MX
AA
494 PR
500 MX
490 AA
1,441 Subjects
483 PR
483 MX
475 AA
Replication of 27 Associated Common Variants
BDR (high/low)
GALA I (18/90 PR, 105/97 MX), SAGE I (57/84 AA), HPR (42/372 PR),
SAPPHIRE (465/557 AA), CHOP (158/122 AA)
Discovery Analysis
Perform ChlP-seq to ldentify H3k27ac Peaks in BSMC
Prioritize Associated Loci for Further Analyses
DiCE Priority Score
Functional Analyses
Luciferase assay, RNA-seq (39 AA)
Identify NFKB1 Loci as Highest Priority for Further Analyses
Figure 1. An overview of the main analyses performed in the current study. More detailed
descriptions of the discovery and replication cohort demographics and analyses performed for
common and rare variant analysis can be found in the METHODS section and the METHODS section in the
online supplement. AA = African American; BDR = bronchodilator drug response; BSMC= bronchial
smooth muscle cell; ChIP-seq = chromatin immunoprecipitation sequencing; CHOP=Children’s
Hospital of Philadelphia; DiCE = Diverse Convergent Evidence; GALA I = Genetics of Asthma in Latino
Americans; GALA II = Genes-Environments and Admixture in Latino Americans; HPR =Hartford–
Puerto Rico cohort; MX =Mexican; PR = Puerto Rican; SAGE = Study of African Americans, Asthma,
Genes and Environments; SAPPHIRE = Study of Asthma Phenotypes and Pharmacogenomic
Interactions by Race-Ethnicity; WGS =whole-genome sequencing.
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European populations (MAF, 3.7–7.6%)
and Puerto Ricans (MAF, 6.2%), and
rare in Mexicans (MAF, 1.5%) (see
Figure E7).
We were unable to identify age- and
population-matched asthma cohorts with
albuterol drug response data of sufficient
sample size for replication. Nevertheless, we
attempted to replicate all 27 SNPs in five
independent populations (GALA I, SAGE I,
HPR, SAPPHIRE, and CHOP) separately
and by meta-analysis (see Tables E10 and
E11). Although none of the 27 SNPs were
significantly associated with BDR status in
our replication analyses (see Table E12),
it is important to note that age-specific
associations with asthma and asthma-
related phenotypes have been reported (31,
32), and that children were not included in
our largest replication cohort (SAPPHIRE,
median age .28) (see Table E10). All
other replication populations were smaller
than our discovery populations (ranging
from 108 to 414 individuals per study), and
some had an imbalance of cases and
control subjects (see Table E10), which
further diminished power for replication
analyses.
Albuterol binds to b2-adrenergic
receptors in BSMC, causing rapid onset
of airway tissue relaxation and
bronchodilation. BSMCs are therefore
considered one of the most relevant cell
types for molecular studies of BDR (33).
We performed H3K27ac ChIP-seq
experiments in primary BSMCs to identify
potential regulatory regions marked by
H3K27ac peaks. We then overlapped the
H3K27ac peaks with the 27 BDR-associated
SNPs and SNPs that were in high LD with
them (R2> 0.8 within 1 Mb in any of our
study populations). Variants overlapping
with H3K27ac peaks may imply regulatory
functions in BSMC (see Table E8).
We applied the Diverse Convergent
Evidence (26) approach to prioritize the 27
BDR-associated SNPs for inclusion in
further functional analyses (see Table E12).
After integrating information from our
WGS analysis, publicly available
bioinformatics data, and ChIP-seq
experiments in BSMCs, the NFKB1 locus
had the highest Diverse Convergent
Evidence score, indicating that NFKB1
had the strongest evidence of functional
relevance to BDR variation (see Figure
E8). Therefore, all further functional
experiments were focused on variants within
this locus.
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Figure 2. (A) Manhattan plot of the transethnic meta-analysis of single locus bronchodilator drug
response association testing. Top 10 bronchodilator drug response–associated loci are circled. The
black line indicates the universal genome-wide significance threshold (5.003 1028), the red line
indicates the adjusted genome-wide significance threshold (3.533 1027), and the blue line indicates
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NFKB1 Functional Assays
Two H3K27ac ChIP-seq regions that
overlapped with the BDR-associated NFKB1
locus were tested for enhancer activity
using luciferase enhancer assays in BSMCs
(see Figure E9A and Table E13). One
enhancer, NFKB1 Region 2, showed
significantly increased enhancer activity
over empty vector (log2 2.24-fold increase,
P = 1.593 1025, unpaired Wilcoxon test)
(see Figure E9B).
Given the relevance of NFKB1 in
immune pathways and asthma, we also
performed RNA sequencing experiments in
African American children with asthma
to verify whether the identified intronic
NFKB1 SNPs regulate expression of
neighboring genes. Among genes within
1 Mb of rs28450894 meeting expression
reliability cutoffs, we found that the low
BDR-associated T allele of rs28450894 is
significantly associated with decreased
expression of SLC39A8 in blood (see Figure
E10) [P = 0.0066, FDR-adjusted P = 0.0856,
log2(b) =20.327].
Comparison with Previous BDR
Association
We observed that two known BDR
candidate genes, ADCY9 and CRHR2,
which replicated in a previous BDR GWAS
performed in the full GALA II population
(18), did not replicate in the current study
(see Table E14). In that study, imputed
GWAS array data were used to evaluate
genetic associations with BDR measured as
a continuous trait. To determine whether
the discrepancy between findings was
caused by data type (imputed array-based
vs. WGS-based) or study design
(continuous trait vs. extreme phenotype),
the common variant analysis in the
current analysis was repeated among the
subset of samples with array-based and
WGS data (n = 1,414 out of 1,441). Based
on the top 1,000 BDR-associated SNPs
from the current common variant analysis,
there was perfect correlation between
association P values generated from
imputed array-based and WGS-based
genotypes (Spearman correlation, 1.0),
suggesting that data type is not the cause
of the observed discrepancy (see Figure
E11A). Nearly all SNPs with high
imputation R2 exhibited high genotype
concordance between array-based and
WGS-based genotypes, confirming high
imputation quality for most common
SNPs (>99.7%; see Figures E11B and
E11C). We also performed linear
regression to analyze BDR as a continuous
trait (DFEV1) using imputed array-based
data. The most significantly associated
SNP identified in the current extreme
phenotype analysis displayed the same
direction of effect as analyzing BDR as a
continuous trait (odds ratio, 1.67 in
extreme phenotype analysis; b = 0.51 in
continuous analysis). These observations
indicate that the discrepancy between
findings may be caused by differences in
statistical power afforded by the different
study designs (continuous trait vs. extreme
phenotype). For common variant analyses,
dichotomization of a continuous outcome
results in a loss of statistical power (34).
The opposite effect is observed in rare
variant analyses. The extreme phenotype
study design has been shown to increase
power and the probability of identifying
functional rare variants (35, 36). Also
noteworthy is that the previously
published results were discovered in one
population (Puerto Ricans), whereas the
results from our transethnic meta-analysis
describe associations that are conserved
across three populations (Puerto Ricans,
Mexicans, and African Americans).
BDR Association Testing Using
Common and Rare Variants
We tested the combined effects of common
and rare variants on BDR using SKAT-O
(37) to examine variants in 1-kb sliding
windows with 500-bp increments. The
same covariates used for common variant
association testing were applied.
After determining the effective number of
tests and adjusting for multiple comparisons
on each population separately, we identified
three population-specific loci associated with
BDR at genome-wide significance levels; two
were found in Mexicans on chromosome
1 and chromosome 11, and one in
African Americans on chromosome
19 (Figures 3A–3C and Table 3; see
Table E15).
We also performed association testing
across all three populations in a single
analysis to maximize power. To minimize
confounding by population substructure,
association testing also included local
genetic ancestry, defined as the
proportions of Native American and
African ancestries for the window under
testing. Two loci on chromosomes 4 and 8
attained genome-wide significance (P,
1.533 1027) (Figure 3D and Table 3).
Sixty variants were identified from all
SKAT-O regions reported in Table 3. Six of
the 60 variants were located within predicted
regulatory regions (see Table E16). Three
variants on chromosome 11 identified in
Mexicans overlap with a CTCF (transcriptional
repressor) binding site and comprise a
chromatin insulator region. The five regions
identified in combined and population-
specific SKAT-O analyses independently
explained 4–8% of BDR variation in their
respective populations (see Table E5).
To investigate whether common
and rare variants both contributed to the
BDR association P value, we performed
reduced and drop-one SKAT analyses by
excluding common or rare variants in the
associated region one by one. Because
excluding either all common or all rare
variants would reduce the significance of
the BDR association P value (see Table
E17), the reduced (see Table E18) and
drop-one (see Table E19) analyses
indicated that both common and rare
variants contribute to the significance of
the BDR association.
Although we believe the sliding
window method is the most appropriate
approach for WGS data, we considered
alternative grouping strategies for rare
variants, including grouping by 1)
genes from transcription start sites to
transcription end sites, with or without
50-kb flanking regions; 2) transcription
start sites with 20-kb flanking regions;
and 3) H3K27ac ChIP-seq peaks from
airway epithelial cells and airway
smooth muscle cells. Association tests
Figure 2. (Continued). the suggestive significance threshold (7.063 1026). (B) Forest plot of the two most significantly associated SNPs, rs17834628 and
rs35661809. The R2 between these two SNPs is 0.93 in Puerto Ricans, 0.96 in Mexicans, and 0.66 in African Americans. (C) The most significantly
associated SNP (rs17834628) is plotted with 400-kb flanking regions on either side. Dot color shows each SNP linkage disequilibrium with rs17834628
based on the 1,000 Genomes November 2014 admixed American population. Multiple SNPs in high linkage disequilibrium (R2. 0.8, red) reached a
suggestive significance level.
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with these grouping strategies identified
no further significant associations.
Because these analyses were performed post
hoc, multiple testing correction for testing
alternative grouping strategies was not applied
to the results of the sliding window approach.
Discussion
We identified population-specific and
shared common and rare variants associated
with BDR in three racially and ethnically
diverse populations of children with
asthma. WGS provides comprehensive
detection of common and rare variants in
coding and noncoding regions. Combined,
the 27 variants (after LD pruning)
identified from our common variant
analyses (Table 2) explained 23%, 16%,
Mexicans
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Figure 3. Manhattan plot of SKAT-O analysis of biallelic common and rare SNPs grouped by 1-kb windows sliding across chromosome 1–22 in (A) Puerto
Ricans, (B) Mexicans, (C) African Americans, and (D) all populations combined. Bonferroni-corrected genome-wide and suggestive significance levels are
marked by red and blue lines, respectively.
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and 18% of the variation in BDR in Puerto
Ricans, Mexicans, and African Americans,
respectively (see Table E5). The five SKAT-O
regions identified in our combined and
population-specific analyses independently
explained 4–8% of BDR variation (Tables 3;
see E5). Our study represents an important
investment from the NIH/NHLBI to
improve racial and ethnic diversity in
clinical and biomedical research.
Our transethnic common variant
meta-analysis identified one locus on
chromosome 5 that was associated with
BDR at a genome-wide significance level
(P, 53 1028). The proximity of this
BDR-associated locus to DNAH5 and
LINC01194 is of particular interest. An SNP
in DNAH5 has been associated with total
lung capacity in white subjects with chronic
obstructive pulmonary disease (38). In a
separate GWAS, the DNAH5/LINC01194
locus was reported among Europeans to be
associated with levels of IgE (39, 40), a
biomarker associated with asthma
endotypes. Baseline lung function (FEV1)
and total IgE levels are associated with
asthma severity and can predispose an
individual to lower BDR (7, 8, 41). We
found two NFKB1 intronic variants on
chromosome 4 that were suggestively
associated with BDR. The nuclear factor-kB
protein has a known role in allergic
response, and various studies have
demonstrated that the nuclear factor-kB
pathway is activated in patients with
asthma, as reviewed by Edwards and
colleagues (42).
ChIP-seq and functional enhancer
assays in BSMCs imply that the
regions containing the NFKB1 intronic
variants regulate expression of nearby
genes, but do not directly suggest that the
genetic variants themselves alter the
expression of nearby genes. However,
the latter was supported by our RNA
sequencing data, which showed that
individuals with the low BDR-associated T
allele displayed reduced expression of
the neighboring SLC39A8 gene.
Additionally, SLC39A8 has been found to
be responsive to cytokine treatment in
airway epithelial cells (42) and had
reduced expression in mice with allergic
airway inflammation (43).
Studies have shown that up-regulation
of SLC39A8 is sufficient to protect the lung
epithelium against tumor necrosis factor-
a–induced cytotoxicity (44). Additionally,
the higher frequency of the low BDR-
associated allele (T allele of rs28450894 in
NFKB1) in African populations suggests
that the low BDR-associated allele tracks
with African ancestry. This may explain
why admixed populations with higher
proportions of African ancestry (e.g.,
African Americans and Puerto Ricans) have
lower BDR (8), and by extension may shed
light on the higher asthma morbidity and
mortality in these populations.
Another intronic variant (chromosome
20, rs16995064, PLCB1 intron 7)
suggestively associated with BDR is
relevant to childhood asthma. PLCB1 is
differentially expressed among children
with therapy-resistant asthma versus
controlled persistent asthma or age-
matched healthy control subjects (45).
Silencing PLCB1 inhibited the effect of
lipopolysaccharide-induced endothelial
cell inflammation by inhibiting expression
of proinflammatory cytokines (46).
Additional functional studies are necessary
to establish the role of NFKB1 and PLCB1
on BDR.
We identified various combined
effects of rare variants that were
population-specific or shared across
populations. Although some nearest
genes show no known functional
relationship to BDR (MAGI3,
LOC105376671, LIN7C, and CPQ), the
locus between ADAMTS3 and COX18
may be functionally relevant. The
ADAMTS3/COX18 locus was associated
with b-adrenergic responses in murine
cardiovascular-related traits (47). This
locus was significantly associated with
cardiac atrial weight in mice treated with
the b-blocker atenolol and replicated
under b-agonist isoproterenol treatment.
These findings suggest that SNPs in this
locus may modify b-adrenergic signaling
pathways in BDR. In the present study, we
also identified BDR association with rare
variants within CPQ, which encodes a
protein from the carboxypeptidase family.
Although no previous BDR association
has been identified for CPQ, another
member of the carboxypeptidase family,
carboxypeptidase A3, is expressed at
higher levels in the airway epithelium
among subjects with Th2-high asthma
(48, 49). Further studies are necessary to
determine the role of CPQ in BDR.
GWAS-based BDR-associated
common variants in GALA II have
previously been reported (18). However,
those variants were not significantly
associated with extreme BDR in the
current study, likely because of differences
in study design. The previous BDR GWAS
used an array-based genotyping panel to
examine children with asthma from the
Table 3. Association Testing for Combined Effects of Common and Rare Variants on BDR
Chr Start Stop P Value Population nCommon nRare Nearest Genes
1 114177000 114178000 4.403 1029 MX 2 1 MAGI3 (intron 9), PHTF1 (62 kb), RSBN1 (126 kb)
11 27507000 27508000 6.593 1029 MX 2 3 LOC105376671 (23 kb), LGR4 (213 kb), LIN7C
(8 kb)
19 10424000 10425000 3.123 10211 AA 1 2 ZGLP1 (24 kb), ICAM5 (217 kb), FDX1L (intron 3),
RAVER1 (2 kb)
4 73478000 73479000 6.253 1028 Combined 10 23 ADAMTS3 (243 kb), COX18 (441 kb)
8 97926000 97927000 1.323 1027 Combined 3 13 SDC2 (2302 kb), CPQ (intron 4), LOC101927066 (37
kb), TSPYL5 (359 kb)
Definition of abbreviations: AA = African Americans; BDR = bronchodilator drug response; Chr = chromosome; MX =Mexicans; nCommon = number of
common variants; nRare = number of rare variants.
Chr, Start, and Stop: GRCh37 chromosome coordinates. Combined: African Americans, Mexicans, and Puerto Ricans. Nearest genes: the four nearest
transcripts from RefSeq were identified, and genes with multiple transcripts were reported once only, with distance to nearest transcripts indicated in
parentheses. Negative distances indicate upstream genes. Genes that overlap with BDR-associated SNPs are bold. Details of all variants within the
windows are presented in Table E16.
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entire BDR spectrum. In contrast, our
current study sequenced the entire genome
to investigate only the extremes of the
BDR distribution. By repeating our current
extreme phenotype analysis using a subset
of individuals who had array and WGS
data, we confirmed that the major
discrepancy between the two studies was
caused by study design instead of
differences in data type. The contrast in
results between GWAS and WGS caused
by differences in study design implies that
varied study designs are necessary for a
comprehensive understanding of variants
associated with asthma-related phenotypes
and drug response. The extreme
phenotype approach is recognized as one
of the success factors in the study design
of pharmacogenomic GWASs (50).
Furthermore, the power gain from
studying extreme phenotypes is much
greater in analyses of rare variants
compared with common variant studies
(51). An extreme phenotype study design
provides a cost-effective means for
studying common and rare variant
associations that may otherwise be missed
when sampling across the entire
phenotypic spectrum.
We did not identify BDR-associated
variants from b2-adrenergic receptors
signaling pathways. Instead, most of the
BDR-associated genes identified in this
study are related to lung function and
allergic response, including total IgE levels
and cytokine production in mast cells. This
suggests that BDR depends in part on the
intrinsic state of airway smooth muscle
cells. Genetic variation may determine
individuals’ intrinsic expression levels of
candidate genes, which in turn determine
whether their response to albuterol is
beneficial.
Including admixed populations in
WGS studies has important scientific
implications. First, it facilitates discovery of
genetic variation of multiple ancestral
populations in a single study. Second,
studying multiethnic admixed populations
with ancestries that are underrepresented in
existing genetic repositories can yield novel
pharmacogenomic insights. For example,
the widely popular PCSK9 inhibitors used to
treat hypercholesterolemia were discovered
by studying the genetics of African
Americans but the drug development
eventually benefited patients of all
ethnicities (52). Finally, studying admixed
populations, such as Mexicans, enhances
the understanding of genetic variation in
Native American ancestry, a population
largely absent in major sequencing
efforts.
We and others have documented the
implications and challenges posed by the
lack of non-European study populations in
biomedical research (53–55). We made
extensive efforts to test our top BDR-
associated variants in other populations,
but the unique characteristics of our
discovery cohort (minority children with
asthma who have BDR and WGS data)
posed significant challenges for finding
comparable replication cohorts. Testing
ancestry-dependent pharmacogenetic
variants without age- and ethnicity-
matched replication populations poses an
impossible statistical bar for publication.
We therefore conducted additional analyses
involving bioinformatics and experimental
assays (56). These challenges highlight the
need to include more racially/ethnically
diverse populations in all clinical and
biomedical research.
In an era of precision medicine,
addressing questions about the impact of
genetic factors on therapeutic drug response
in globally diverse populations is essential
for making precision medicine socially and
scientifically precise (57). This study
advances the understanding of genetic
analysis in admixed populations and helps
to lay the foundation of precision medicine
for understudied and racially and ethnically
diverse populations. n
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